@article {ThonS2作者={杰西·索恩和罗伯特·塔迦尔Sharkus和理查德克里斯托猎人和詹姆斯Siegler奥尔加索恩},title = {FDA批准治疗视神经节Neuromyelitis谱系障碍临床实践:一项调查学术Neuroimmunologists},体积={99},数量={23补充2},页面= {S2 - S2} = {2022}, doi = {10.1212/01. wnl.0000903060.69682.6b},出版商= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={目的评估利用率和使用障碍三个最近FDA批准的治疗视Neuromyelitis学术Neuroimmunologists谱系障碍(NMOSD)。首页背景自2019年以来,eculizumab、inebilizumab satralizumab收到FDA批准用于治疗aquaporin-4免疫球蛋白阳性(AQP4 +) NMOSD后显示效果在减少攻击频率。然而,所知甚少的采用这些治疗方法付诸实践或使用障碍。我们进行了一项调查学术neuroimmunologists识别当前的治疗实践。设计/方法neuroimmunologists电子调查研究的我们。接受者被确定在部门网站上的university-associated与附属医院神经病学派驻。首页这项调查是通过电子邮件管理,包括与临床相关的问题背景,病人组,治疗用在不同的场景中,障碍。作者对受访者的身份也不清楚。结果383 neuroimmunologists从105年机构确认,其中33从18个州完成了调查。几乎所有(88 \ %)报道,美国fda批准的新疗法患者(非功能性测试)。没有报道不适与病人讨论任何非功能性测试。受访者表示非同寻常的临床稳定的病人转向非功能性测试(69 \ %从来没有开关,22 \ %开关1 - 25 \ %的时间)。 For newly diagnosed AQP4+ NMOSD patients, NFT initiation rates varied (16\% initiate none, 42\% 1-25\% of the time, 6.5\% 25-50\%, 19\% 50-75\%, 16\% 75-100\%). For patients with a relapse, responses were dichotomized regarding switching to NFTs - respondents either switch 75-100\% of their patients (60\%) or none or 1-25\% (16\%, 24\% respectively). Nearly half (16/33) of respondents reported being unable to start NFTs, with insurance/cost issues being the most cited barrier.Conclusions Among academic neuroimmunologists, FDA-approved therapies for AQP4+ NMOSD are being utilized for newly diagnosed patients and those with disease recurrence, although individual practice patterns vary. The main perceived barriers to NFT use are insurance/cost-related issues.}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/99/23_Supplement_2/S2.1}, eprint = {//www.ez-admanager.com/content/99/23_Supplement_2/S2.1.full.pdf}, journal = {Neurology} }